KZIA Stock — Kazia Therapeutics Limited: Cash, EV, Pipeline

What they do

Our agent for service of process in the United States is Vcorp Services, LLC, 25 Robert Pitt Drive, Suite 204, Monsey, New York 10952. The Company’s ADSs, each representing five-hundred Ordinary Shares, trade on the Nasdaq Capital Market under the symbol ‘KZIA’.

Source: 20-F FY2025 via SEC EDGAR

Share price

$7.18

Market cap

$111.6M

Cash

$3.0M

Enterprise value

$108.6M

Balance sheet

Cash	$3.0M
Debt	$0.0M
Net cash	$3.0M
Enterprise value	$108.6M
Basic shares	4.7M shares
Fully diluted shares	9.0M shares
Fully diluted market cap	$64.7M
Cash per share	$0.64

Cash figures as of 2025-06-30. Database snapshot: 2026-11-07.

Share structure

Common

4.7M

Pre-funded warrants

—

Options

—

RSUs

—

Warrants

4.3M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

9.0M

Cap table components pending verification.

Price history

Loading KZIA daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

Paxalisib

Stage not disclosed · Active Modality: small molecule

Aliases GDC-0084

Target PI3K/Akt/mTOR

Status note Lead program; small molecule inhibitor of the PI3K/Akt/mTOR pathway in clinical trials. Filing excerpts do not disclose the indication or trial phase for this filing period.

EVT801

Stage not disclosed · Active Modality: small molecule

Target VEGFR3

Status note Small molecule selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3) in clinical trials. Filing excerpts do not disclose the indication or trial phase for this filing period.

Per-asset detail extracted from the 20-F filed 2025-11-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Boxer Capital	560,000	+560,000	0.59%	2026-08-14
Ikarian Capital	396,201	+396,201	0.91%	2026-08-14
Stonepine Capital	345,179	no change	3.70%	2026-08-17
ADAR1 Capital Management	61,550	+61,550	0.04%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

KZIA — Kazia Therapeutics Limited ☆